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evated in patients with ulcerative colitis [32% (IQR 9) vs. 27% 
(IQR 8) in controls], and maximum expiratory flows at 50 and 
25% of vital capacity were mildly reduced in patients with 
Crohn’s disease. FeNO and disease activity did not correlate 
with lung function abnormalities. Abnormalities did not con-
sistently persist over a median follow-up period of 34 months. 
 Conclusions: This study supports evidence that variable and 
fluctuating pulmonary involvement also occurs in pediatric 
IBD patients. Its clinical significance is unclear. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Increasing evidence suggests that the prevalence of as-
ymptomatic respiratory involvement is underestimated 
in adult patients with inflammatory bowel disease (IBD) 
 [1–7] , and recent reviews have emphasized that adult pa-
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 Abstract 
 Background: Pulmonary involvement in adult patients with 
inflammatory bowel disease (IBD) seems more common than 
previously appreciated. Its prevalence and development over 
time in pediatric IBD patients are largely unknown.  Objec-
tives: The aim was to study lung function including fraction 
of exhaled nitric oxide (FeNO) and transfer capacity for carbon 
monoxide (TLCO) in pediatric IBD patients and to describe the 
longitudinal development in a subset of patients with lung 
function abnormalities.  Methods: Sixty-six measurements 
were made in 48 IBD patients (30 patients with Crohn’s dis-
ease and 18 with ulcerative colitis) and 108 matched controls. 
Patients with abnormal TLCO or elevated residual volume/to-
tal lung capacity (RV/TLC) ratios were invited for a follow-up. 
Statistical comparisons were made by nonparametric tests 
and ANOVA.  Results: TLCO was decreased in IBD patients 
[median: 88% predicted (interquartile range, IQR, 22) vs. 99% 
predicted (IQR 19) in controls]. RV/TLC ratios were mildly el-
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tients should be systematically monitored for lung disease 
 [3, 8, 9] . In contrast, a recent audit among participants of 
the EUROKIDS IBD registry, an ESPGHAN (European 
Society for Paediatric Gastroenterology, Hepatology and 
Nutrition) task force, describing the current state-of-the-
art diagnostic work-up in pediatric IBD as well as the un-
derlying 2005 ESPGHAN guidelines, suggest that pulmo-
nary involvement is not considered a feature of pediatric 
IBD that warrants systematic and regular investigation 
 [10, 11] . In fact, there are insufficient data to determine 
the prevalence, significance, and evolution of respiratory 
involvement in the pediatric IBD population. Published 
studies comprise around 90 children in total, and results 
are contradictory. Munck et al.  [12] reported a persistent-
ly reduced transfer capacity for carbon monoxide (TLCO) 
even during clinical remission in a majority of 25 children 
with Crohn’s disease (CD), and Mansi et al.  [13] found 
bronchial hyperresponsiveness in 10 out of 14 children 
with CD. In contrast, a recent study from Poland includ-
ing 25 ulcerative colitis (UC) and 25 CD patients con-
cluded that respiratory involvement is unusual in chil-
dren with IBD  [14] .
 The primary objective of the current study was to as-
sess the prevalence and clinical significance of pulmonary 
involvement in children with IBD in a three-center case-
controlled study; a secondary aim was to assess the per-
sistence of lung function abnormalities longitudinally.
 Materials and Methods 
 Subjects 
 All children with IBD attending the outpatient gastrointestinal 
clinics of the participating institutions were eligible for this study. 
Exclusion criteria were a respiratory tract infection within the 
precedent 3 weeks, denial or withdrawal of consent, and the in-
ability to perform reproducible lung function measurements. The 
study was approved by the local ethics committees of the institu-
tional review boards (EK318/06), and parental and patients’ writ-
ten informed consent were obtained from all participants. Each 
patient was carefully matched to two controls by sex, height, age, 
and weight. The controls were recruited from patients referred to 
the pulmonary outpatient clinics for exercise intolerance of un-
clear etiology or nonspecific dry cough and were not found to 
have current lung disease. Delayed puberty and growth failure are 
not uncommon in IBD patients  [15] . IBD patients were thus ex-
pected to have lower weight and height for age; therefore, recruit-
ing controls matched primarily for height and sex, followed by age 
and weight, was considered more appropriate to provide optimal-
ly matched controls than recruiting age- and sex-matched con-
trols from the general population. This was considered particu-
larly important with regard to TLCO, the primary lung function 
variable in focus, which is mainly predicted by sex and height in 
children  [16] . All patients and controls were of Caucasian origin. 
The first recruited patient was registered in Mai 2004, and patients 
were recruited up to November 2011. The last follow-up was in 
June 2013.
 Study Design 
 All patients underwent clinical assessment, blood sampling for 
hemoglobin (Hb), and lung function testing including maximum 
expiratory flow volume curves and body plethysmography, TLCO, 
and measurement of the fraction of exhaled nitric oxide (FeNO). 
Patients with an increased residual volume/total lung capacity 
(RV/TLC) ratio of >30% or with an Hb-corrected TLCO <75% of 
predicted were invited for a follow-up assessment after a mean in-
terval of 2.8 ± 2.8 years. Clinical IBD activity in CD was document-
ed by means of the abbreviated Paediatric Crohn’s Disease Activ-
ity Index (PCDAI), which excludes laboratory variables and 
growth velocity of the original PCDAI but correlates well with the 
latter  [17] . As no pediatric UC activity score was available at the 
time of study initiation, the Simple Clinical Colitis Activity Index 
(SCCAI), which had been developed for adult patients, was used 
for UC patients  [18] . In addition, treatment history and respira-
tory symptoms were documented. Allergic sensitization was de-
rived from the personal history, skin prick testing, and/or specific 
IgE testing to the most common inhalant allergens (silver birch, 
timothy, rye, and mugwort pollen, cat and dog dander,  Derma-
tophagoides pteronyssinus , and  Cladosporium herbarum ) by im-
munoallergosorbent testing (ImmunoCAP sx1, Phadia GmbH, 
Freiburg, Germany).
 Lung Function Testing 
 FeNO was measured online by the single-breath method using 
a chemiluminescence NO analyzer (CLD 77 AM, Eco Physics, 
Dürnten, Switzerland) according to the American Thoracic Soci-
ety/European Respiratory Society (ATS/ERS) guidelines after in-
haling NO-depleted ambient air (Denox 88, Eco Physics)  [19, 20] . 
Measurements were made in triplets at 30-second intervals, and 
the mean was taken for analyses. Spirometry, body plethysmogra-
phy, and TLCO measurements (MasterScreen and MasterLabPro, 
Erich Jaeger GmbH, Höchberg, Germany) were performed in ac-
cordance with established ATS/ERS guidelines after the comple-
tion of FeNO measurements  [21–23] . Data were referenced to the 
normal data by Polgar and Promadhat  [24] and Zapletal et al.  [25] . 
TLCO single-breath measurements were corrected for Hb in IBD 
patients according to the ATS/ERS recommendations  [26] and ac-
cording to the equations proposed by Marrades et al.  [27] after 
conversion to SI units. As blood samples were not obtained from 
controls, TLCO adjustments were made in the control group for 
an assumed Hb of 146 g/l in males older than 15 years and for an 
assumed Hb of 134 g/l for boys younger than 15 years and for girls 
 [28] . Predictions for TLCO and TLCO/alveolar volume (VA) were 
those referenced by de Jongste et al.  [16] , and TLCO/VA values 
were compared to predictive values after Hb correction according 
to Marrades et al.  [27] .
 Statistical Analysis 
 Patient and control characteristics are presented descriptively. 
Continuous variables are expressed as medians with interquartile 
ranges (IQR), unless stated otherwise. Normal distribution of the 
data was checked by visual inspection of Q-Q plots and formally 
tested by the Shapiro-Wilk test; t tests were used to test mean dif-
ferences between two groups. Overall differences of group means 
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were analyzed by one-way analysis of variance (ANOVA) and 
overall differences of group medians by the nonparametric Krus-
kal-Wallis test. Being more robust, the latter was selected for data 
interpretation and reporting of p values. Serial measurements were 
made in 15 patients, and values were compared by the Mann-
Whitney U test. Spearman’s rank order correlation was used to 
explore the relationship between activity scores and lung function 
measures. All analyses were performed using IBM SPSS Statistics 
software version 20.0 (IBM Corp., Armonk, N.Y., USA). A p value 
of <0.05 was considered statistically significant. 
 Results 
 Sixty-six measurements were made in a total of 48 pa-
tients aged 13.6 years (IQR 2.7), matched to 108 controls 
(12 controls being matched to two measurements). Eigh-
teen patients suffered from UC (8 females) with a median 
SSCAI of 1 [IQR 5.5 (range 0–20)], and 30 had CD (8 fe-
males) with a median PCDAI of 5 [IQR 13 (range 0–20]. 
Hb was 117.6 g/l [IQR 18.0 (range 71–146)] in the patient 
group.
 There were differences between the groups for 
TLC %  predicted (p < 0.05), RV/TLC ratio (p < 0.05), and 
maximum expiratory flow values at 50 and 25% (MEF50 
and MEF25) of vital capacity (VC; p < 0.01;  table 1 ). Sub-
group analyses revealed that increased RV/TLC ratios 
were attributable to children with UC (p < 0.01), in whom 
an increased RV/TLC ratio >0.30 was present in 54% of 
cases. In contrast, mild reductions of median mid- and 
end-expiratory flow values were found in children with 
CD ( table 1 ). However, merely 8% of CD cases had abnor-
mal forced expiratory volume in 1 second (FEV 1 ) % pre-
dicted values (<80% predicted).
 Predicted TLCO values were significantly lower in the 
IBD group (p < 0.001) and remained significantly lower 
than in controls after Hb correction according to the 2005 
ATS/ERS recommendations  [26] (p < 0.01), with 17% of 
measurements in IBD patients versus 6% in controls be-
ing below an arbitrary lower threshold of 75% predicted 
( table  2 ). Of note, TLCO values were not significantly 
lower in CD patients than in controls when applying the 
correction equations by Marrades et al.  [27] (p = 0.24; 
 table 2 ). 
 Median FeNO in IBD patients was 11.6 ppb [IQR 7.8 
(range 4–78)], with no significant differences between 
CD and UC (p = 0.9). Allergic sensitization was docu-
mented in 13/47 (28%) of IBD patients (UC: 12%, CD: 
37%), in 2/8 patients with FeNO 20–30 ppb (4 UC, 4 CD), 
and in 3/4 patients with FeNO >30 ppb (2 UC, 2 CD). 
However, neither FeNO nor expiratory flow values were 
associated with the allergic sensitization in this cohort. 
Fifty-two of 66 (79%) of FeNO measurements were per-
 Table 1. Antropometric and spirometry/body plethysmography data
All IBD patients
(n = 48, 66 mea-
surements)
CD patients
(n = 30, 38 mea-
surements)
UC patients
(n = 18, 28 mea-
surements)
Controls
(n = 108, 122 
matched tests)
p valuea
Age, years 13.6 (12.6; 15.3) 13.4 (12.2; 14.8) 14.5 (12.7; 15.7) 13.5 (12.1; 14.9) n.s.
Weight, kg 49.5 (40; 55) 48.8 (37; 54) 50.0 (42; 56) 48.0 (38; 55) n.s.
Height, cm 155 (149; 165) 153 (143; 161) 161 (153; 168)* 156 (149; 165) n.s.
TLC, l 4.2 (3.4; 5.2) 3.9 (3.2; 5.0) 4.9 (4.0; 5.4)* 4.3 (3.7; 5.2) <0.05
TLC, % 101.7 (93; 109) 99.6 (90; 107)** 103.8 (98; 109) 103.8 (97; 109) <0.05
RV/TLC 28.9 (26; 34) 27.8 (23; 33) 31.9 (27; 36)** 26.9 (23; 31) <0.05
FVC, l 2.9 (2.4; 3.6) 2.8 (2.4; 3.4) 3.2 (2.6; 3.9) 3.1 (2.5; 3.7) n.s.
FVC, % 93.9 (86; 102) 96.0 (88; 101) 90.9 (82; 105) 97.2 (87; 106) n.s.
FEV1, l/s 2.6 (2.1; 3.2) 2.5 (2.0; 3.0) 2.9 (2.4; 3.5) 2.7 (2.3; 3.2) n.s.
FEV1, % 99.9 (93; 107) 99.9 (92; 104)* 100.4 (95; 109) 107.4 (96; 115) n.s.
FEV1/VC 88.3 (82; 92) 89.4 (84; 93) 87.7 (80; 92) 87.5 (83; 90) n.s.
MEF50, l/s 3.4 (2.3; 4.3) 3.1 (2.2; 3.9) 4.0 (3.0; 4.9)** 3.4 (2.8; 4.0) <0.01
MEF50, % 92.7 (80; 103) 89.0 (74; 99)* 101.2 (89; 110) 96.1 (83; 106) <0.05
MEF25, l/s 1.6 (1.1; 2.2) 1.4 (0.9; 1.8) 2.0 (1.3; 2.3)** 1.6 (1.3; 2.1) <0.01
MEF25, % 84.3 (65; 106) 75.9 (61; 97)* 98.7 (77; 113)* 90.4 (73; 104) <0.01
 Numbers indicate medians and IQR in parentheses. n.s. = Not significant. a p values for overall differences 
between groups (Kruskal-Wallis test). * p < 0.05, ** p < 0.01; p values for two group comparisons (controls vs. 
CD and UC, respectively).
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formed under immunosuppressive or immunomodula-
tory treatment. There were no significant differences in 
FeNO between children with or without immunosup-
pressive or immunomodulatory treatment (p = 0.6). 
 Various correlation analyses querying interactions of 
the RV/TLC ratio, FEV 1 % predicted , TLCO, duration of dis-
ease, age, FeNO, and clinical activity scores showed a cor-
relation of the RV/TLC ratio with duration of disease 
(r = –0.5, p < 0.01) and a borderline correlation of the 
RV/TLC ratio with disease activity in CD (r = –0.3, p = 
0.05). No other correlations were found.
 Patients with either an abnormal RV/TLC ratio (>30%) 
or a decreased TLCO value (<75% predicted) at the initial 
assessment were invited for a follow-up visit, and 18 se-
rial measurements were made with an interval of 2.8 ± 2.8 
years. The RV/TLC ratio decreased from 32 ± 6 to 28 ± 
5% (p < 0.01). No differences between the two measure-
ments were found for any other variable. Notably, 
TLCO % predicted and expiratory flow abnormalities did not 
consistently persist over time ( fig. 1 ).
 Discussion 
 The IBD patients in this cohort showed lower TLCO 
and mid- and end-expiratory flow values than controls, 
albeit only a minority of patients had reduced lung func-
tion below the normal range. Impaired TLCO was found 
in both CD and UC patients, while flow reductions were 
attributable to CD patients, and an increased RV/TLC ra-
tio was seen in UC patients. Longitudinal assessment in 
this series did not show persistence of abnormalities over 
a mean observation period of almost 3 years. 
 Clinically overt respiratory disease in IBD shows con-
siderable variability, affecting the airways, the parenchy-
ma, and/or the pleura  [29–34] . Respiratory symptoms, 
however, are rare, and bronchopulmonary involvement 
is assumed to remain clinically silent in the majority of 
cases. A transbronchial biopsy study in adult UC patients 
with no concurrent pulmonary symptoms indeed re-
vealed variable degrees of mononuclear cell infiltration 
and/or fibrosis in 8 out of 10 patients  [6] . Bronchoalveo-
lar lavage studies in patients with clinically inactive IBD 
similarly showed increased counts of inflammatory cells, 
usually with a mononuclear predominance, implying on-
going pulmonary inflammation even during clinical re-
mission  [4–6] . 
 A reduced TLCO is the most frequently reported ab-
normality in IBD patients. Studies in adults also suggest-
ed that lung function changes may correlate with disease 
activity, but, consistent with the bronchoalveolar lavage 
studies, persistent lung function abnormalities are also 
found in a substantial subset of individuals without pul-
monary symptoms during IBD remission  [1–3, 7, 35–39] .
 Our results corroborate that TLCO may indeed be 
mildly reduced in many IBD patients. The biological basis 
of this TLCO reduction, however, remains unclear. A 
normal (instead of a reduced) VA/TLC ratio argues 
against airway obstruction and ventilation inhomogene-
ity being the underling pathogenic mechanisms. As both 
TLCO and the rate constant for CO uptake (TLCO/VA) 
were reduced in our population, we would preclude that 
 Table 2. Carbon monoxide uptake capacity of the lungs
All IBD 
patients
CD patients UC patients Controls p valuea
TLCO, mmol/min/kPa 6.1 (5.2; 7.7) 5.8 (4.9; 7.7)* 6.3 (5.5; 7.8) 7.1 (6.2; 8.1) 0.06
TLCO, %
Range
80.0 (73; 93)
37 – 122
85.3 (71; 98)**
37 – 122
77.7 (73; 89)***
57 – 121
97.4 (88; 106)
58 – 129
<0.001
TLCO Hb-corr, %b
Range
88.2 (78; 100)
39 – 142
92.2 (79; 105)*
39 – 118
86.4 (78; 94)***
61 – 142
98.8 (89; 107)
63 – 127
<0.01
TLCO Hb-corr, %c
Range
94.2 (82; 109)
54 – 145
95.7 (82; 110)
54 – 129
88.9 (77; 99)
58 – 145
97.2 (88; 106)
63 – 127
n.s.
TLCO Hb-corr/VA, %
Range
94.0 (90; 99)
73 – 125
93.6 (90; 98)
76 – 125
97.5 (92; 100)
73 – 117
100.1 (97; 102)
78 – 116
n.s.
Numbers indicate medians and IQR in parentheses unless otherwise indicated. Hb-corr = Hb correction; 
n.s. = not significant. a p values for overall differences between groups (Kruskal-Wallis test). b Hb correction 
according to MacIntyre et al. [26]. c Hb correction according to Marrades et al. [27]. * p < 0.05, ** p < 0.01; 
p values for two group comparisons (controls vs. CD and UC, respectively). 
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the impaired TLCO in IBD was due to incomplete VC 
maneuvers  [40] . In theory, the reduced TLCO may be 
caused by changes in the alveolar membranes or in the 
pulmonary vasculature such as capillary paucification or 
intrapulmonary shunting. Current concepts of IBD 
pathogenesis suggest that an imbalance between defense 
against and tolerance of the intestinal flora leads to an al-
tered composition and reduced biodiversity of the micro-
bial flora, a deregulated and overshooting immune re-
sponse, and a disruption of the epithelial barrier function 
 [41–43] . There is evidence suggesting that some immu-
noreactive cells in IBD do not remain homed in the gut 
but recirculate to other tissues such as the lung  [44] , al-
lowing intense cross-talk between intestinal and pulmo-
nary immune cells  [45] . Thus, inflammation may con-
tribute to the mildly impaired TLCO.
 The present study underscores that TLCO measure-
ment without Hb correction is inappropriate in anemic 
patients. Blood samples are often reluctantly drawn in 
children, but Hb correction had a major impact on TLCO 
results in this cohort, and it is noteworthy that a fair num-
ber of published studies did not describe whether and 
how anemia had been accounted for. As no Hb values 
were available for the controls in this study, the relatively 
crude recommended estimations were used subsidiarily 
 [26] . Using the 50th percentile of an alternative Hb refer-
ence  [46] , however, did not change the results of the 
study.
 Airway obstruction both in UC and in CD has been 
reported in some but not all cohorts  [7, 12, 14, 47–50] . We 
found mildly decreased mid- and end-expiratory flow 
values in CD patients compared to controls, while the 
larger airways seemed unaffected as reflected by normal 
FEV 1 and FEV 1 /VC values. This is in line with a previous 
study in 30 adult patients which concluded that the func-
tion of the small airways was affected in IBD  [39] , and it 
concurs with studies reporting air trapping in IBD by 
 imaging studies  [3, 33] . However, we could not detect 
 significant air trapping by differentiating functional re-
sidual capacity (FRC) measured by plethysmography 
(FRC pleth ) from FRC measured by Helium dilution 
(FRC He )  [22] , neither were RV/TLC ratios correlated 
with disease activity, which could imply incomplete exha-
lation due to abdominal discomfort. Only three studies in 
adults so far have reported RV/TLC ratios, two of which 
described elevated RV/TLC ratios  [3, 48, 51] . The inher-
ently large variability in measured peripheral airway 
flows needs to be taken into account when interpreting 
MEF50 and MEF25, rendering these results less robust. 
Ventilation inhomogeneity measures might be a valuable 
p < 0.01
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tool to corroborate subclinical disease activity at the level 
of the small airways  [52] . 
 A few studies have revealed an increased prevalence 
of bronchial hyperreactivity in both atopic and non-
atopic IBD patients  [1, 13, 53] . We did not test for bron-
chodilator responsiveness, as the protocol foresaw ad-
ministration of salbutamol only when baseline spirom-
etry was suggestive of airway obstruction. We therefore 
cannot exclude that asthma or atopy contributed to air-
way obstruction in some of our CD patients, but neither 
the presence of atopy nor FeNO were significantly re-
lated to lung function results. An increased prevalence 
of atopy in IBD patients has been described in some but 
not all previous studies  [1, 53, 54] . The apparent con-
trariness of an increased atopy prevalence in CD and its 
alleged TH 1 -dominated immunology has recently been 
put into new perspective with the recognition of the 
complexity of immunologic reactions involved in IBD 
 [43] .
 The misdirected inflammatory activity that character-
izes IBD is associated with an overproduction of reactive 
oxygen and nitrogen metabolites in the gut  [55–57] . 
These reactive species contribute to mucosal injury, re-
duced perfusion, poor wound healing, and maintenance 
of chronic inflammation  [55] . In the lung, FeNO corre-
lates reasonably well with eosinophilic airway inflamma-
tion, which has facilitated monitoring of disease activity 
in atopic asthma  [58, 59] , but FeNO is of limited value for 
assessing mucosal airway inflammation in noneosino-
philic airway disease  [60] .
 It has been hypothesized that nitrogen pathways may 
contribute to IBD-associated lung disease, and its metab-
olites may serve as markers of pulmonary involvement in 
IBD  [47, 50] . Since Koek et al.  [47] have reported a sig-
nificant correlation of FeNO with disease activity in 55 
adult IBD patients, a number of subsequent studies eval-
uating FeNO as an indicator of pulmonary involvement 
in IBD have revealed conflicting results  [14, 48, 50]. UC 
seemed to be associated with higher FeNO levels than CD 
 [14, 47, 48] . The mean FeNO levels associated with IBD 
in positive studies, however, were low, in the range of 10–
30 ppb, and most patients were under some immuno-
modulatory treatment. As FeNO is sensitive to corticoste-
roid treatment in most allergic asthma patients  [61] , it 
may be speculated that immunosuppressive IBD therapy 
affects FeNO levels. Alternatively, however, the negative 
FeNO results in this study may imply that airway inflam-
mation in IBD, if present, is not predominantly an eo-
sinophilic inflammation  [53, 60] . 
 Strengths of this study are the size of the cohort, which 
substantiates the data on pulmonary involvement in pe-
diatric IBD patients and allows a comparison of UC with 
CD, and the inclusion of longitudinal data. Weaknesses 
are that we were not able to assess bronchial hyperrespon-
siveness and that follow-up data were available for a lim-
ited number of patients only.
 In conclusion, the present study supports existing evi-
dence that pulmonary function abnormalities in IBD do 
occur in children and adolescents, irrespectively of intes-
tinal disease activity. Lung function changes, however, 
are usually very mild and do not seem to persist longitu-
dinally. These abnormalities suggest variable and fluctu-
ating pulmonary involvement in pediatric IBD and may 
thus add to our understanding of IBD, but clinical impact 
during childhood seems limited. We thus argue that at the 
time being, regular lung function testing in pediatric IBD 
patients without respiratory symptoms is not mandatory 
in clinical routine. 
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